New drug cocktail shows promise for Hard-to-Treat blood cancer

NCT ID NCT02718833

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 27 times

Summary

This study tests a combination of four drugs (elotuzumab, pomalidomide, bortezomib, and dexamethasone) in 52 adults with multiple myeloma that has returned or not responded to at least two prior treatments. The goal is to see how many patients achieve at least a partial response and to monitor side effects. Participants receive the drugs in cycles, and the study is active but no longer recruiting.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02115, United States

  • Mass General/North Shore Cancer Center

    Danvers, Massachusetts, 01923, United States

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts, 02114, United States

  • Newton-Wellesley Hospital

    Newton, Massachusetts, 02462, United States

  • University of Michigan

    Ann Arbor, Michigan, 48109, United States

  • University of Rochester

    Rochester, New York, 14642, United States

Conditions

Explore the condition pages connected to this study.